Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Gw Pharma ADR (GWPH)

Gw Pharma ADR (GWPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,752,516
  • Shares Outstanding, K 30,890
  • Annual Sales, $ 12,730 K
  • Annual Income, $ -295,160 K
  • 60-Month Beta 2.23
  • Price/Sales 286.44
  • Price/Cash Flow N/A
  • Price/Book 5.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.86
  • Number of Estimates 8
  • High Estimate -0.60
  • Low Estimate -1.08
  • Prior Year -2.76
  • Growth Rate Est. (year over year) +68.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
105.10 +15.59%
on 10/02/19
133.50 -9.00%
on 09/23/19
-7.44 (-5.77%)
since 09/20/19
3-Month
105.10 +15.59%
on 10/02/19
175.35 -30.72%
on 08/08/19
-43.98 (-26.58%)
since 07/19/19
52-Week
90.14 +34.77%
on 12/27/18
196.00 -38.02%
on 05/07/19
-21.11 (-14.80%)
since 10/19/18

Most Recent Stories

More News
GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know

GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $118.11, moving -0.85% from the previous trading session.

GWPH : 121.48 (+2.85%)
Abbott Forms Alliance With Omada Health for Diabetes Care

Abbott (ABT) collaborates with Omada Health to revolutionize diabetes care by expanding technological access.

SNY : 45.94 (-0.50%)
ABT : 81.65 (-1.38%)
OMI : 7.23 (+1.26%)
GWPH : 121.48 (+2.85%)
Cannabis 2.0: Canada Set to Legalize CBD Topicals and Beverages October 17, 2019

Over the next three days, Canada will legalize CBD all over again. Just a year after legalizing dried cannabis flower, oils, and sprays, Canada will now legalize edibles, beverages, and topicals this Thursday,...

OGRMF : 8.3500 (+4.64%)
BOSS.CN : 0.300 (-11.76%)
BOSQF : 0.2400 (-8.57%)
APHA : 4.82 (+1.47%)
APHA.TO : 6.27 (+0.48%)
CWEB.CN : 19.300 (+1.85%)
CWBHF : 13.3000 (-0.37%)
OGI.VN : 6.850 (-0.44%)
OGI : 3.56 (-1.11%)
GWPH : 121.48 (+2.85%)
CHF Solutions System to be Used in JAHVH Study After Final Nod

CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.

SYK : 215.07 (-0.12%)
CAPR : 2.61 (-2.97%)
GWPH : 121.48 (+2.85%)
CHFS : 1.42 (-6.58%)
Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes

Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.

PAHC : 21.54 (+2.13%)
SYK : 215.07 (-0.12%)
GWPH : 121.48 (+2.85%)
CNAT : 0.34 (-8.61%)
Penumbra Enrolls First Patient for Study on Coronary Vessels

Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.

PEN : 147.63 (+0.29%)
SYK : 215.07 (-0.12%)
GWPH : 121.48 (+2.85%)
CNAT : 0.34 (-8.61%)
The Psilocybin Mushroom Story Could be the Next Big Investment Boom

As the cannabis market booms, another drug may soon follow in its footsteps -- psilocybin mushrooms. Already, we're seeing a groundswell of interest. In fact, activists in California are working on getting...

BOSS.CN : 0.300 (-11.76%)
BOSQF : 0.2400 (-8.57%)
GWPH : 121.48 (+2.85%)
TLRY : 22.44 (+5.01%)
APHA : 4.82 (+1.47%)
APHA.TO : 6.27 (+0.48%)
TGOD.TO : 1.15 (-3.36%)
TGODF : 0.8801 (-2.21%)
QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits

QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

GWPH : 121.48 (+2.85%)
QGEN : 28.11 (-1.33%)
ILMN : 313.83 (+1.42%)
INO : 2.32 (+3.11%)
How to Invest in Emerging Industries Like Marijuana

Investors are still crazy about the pot stocks despite this year's roller coaster ride.

GWPH : 121.48 (+2.85%)
IIPR : 73.60 (+1.46%)
ACB : 3.69 (+0.27%)
CGC : 20.35 (+0.69%)
MJ : 19.92 (+1.58%)
Is GW Pharmaceuticals (GWPH) Stock Outpacing Its Medical Peers This Year?

Is (GWPH) Outperforming Other Medical Stocks This Year?

GWPH : 121.48 (+2.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade GWPH with:

Business Summary

GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and...

See More

Key Turning Points

2nd Resistance Point 124.70
1st Resistance Point 123.09
Last Price 121.48
1st Support Level 119.71
2nd Support Level 117.94

See More

52-Week High 196.00
Fibonacci 61.8% 155.56
Fibonacci 50% 143.07
Fibonacci 38.2% 130.58
Last Price 121.48
52-Week Low 90.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar